Association of funding and findings of pharmaceutical research at a meeting of a medical professional society

Thomas Finucane, Chad E. Boult

Research output: Contribution to journalArticle

Abstract

To evaluate the association between funding and findings of pharmaceutical research presented at an annual meeting of a medical professional society. We reviewed the abstracts of all papers and posters presented at the annual meeting of a medical professional society. Two independent raters classified each study of a drug (n = 48) as either positive (favoring the drug studied) or negative, and as either funded by a pharmaceutical company or not. We computed κ and chi-squared statistics to evaluate the agreement between the raters, as well as the association between the results and the sponsorship of the study. Thirty studies of drugs (63%) were supported by pharmaceutical companies, all of which reported positive results. Of the 18 studies (37%) not supported by pharmaceutical companies, 67% reported positive results. The association between pharmaceutical funding and positive findings was statistically significant (P = 0.0007). At this scientific meeting, research funding from pharmaceutical companies was associated with study findings that supported the use of drugs marketed by pharmaceutical sponsors. We emphasize further study of this relation and suggest three principles - full disclosure, policies against "outcome bias," and educational opportunities - that may help manage industry-academia conflicts of interest that could otherwise jeopardize the credibility of pharmaceutical research presented at scientific meetings.

Original languageEnglish (US)
Pages (from-to)842-845
Number of pages4
JournalAmerican Journal of Medicine
Volume117
Issue number11
DOIs
StatePublished - Dec 1 2004

Fingerprint

Medical Societies
Pharmaceutical Preparations
Pharmaceutical Research
Conflict of Interest
Posters
Disclosure
Industry

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Association of funding and findings of pharmaceutical research at a meeting of a medical professional society. / Finucane, Thomas; Boult, Chad E.

In: American Journal of Medicine, Vol. 117, No. 11, 01.12.2004, p. 842-845.

Research output: Contribution to journalArticle

@article{91c49b3f64f04448a68a471d655e7376,
title = "Association of funding and findings of pharmaceutical research at a meeting of a medical professional society",
abstract = "To evaluate the association between funding and findings of pharmaceutical research presented at an annual meeting of a medical professional society. We reviewed the abstracts of all papers and posters presented at the annual meeting of a medical professional society. Two independent raters classified each study of a drug (n = 48) as either positive (favoring the drug studied) or negative, and as either funded by a pharmaceutical company or not. We computed κ and chi-squared statistics to evaluate the agreement between the raters, as well as the association between the results and the sponsorship of the study. Thirty studies of drugs (63{\%}) were supported by pharmaceutical companies, all of which reported positive results. Of the 18 studies (37{\%}) not supported by pharmaceutical companies, 67{\%} reported positive results. The association between pharmaceutical funding and positive findings was statistically significant (P = 0.0007). At this scientific meeting, research funding from pharmaceutical companies was associated with study findings that supported the use of drugs marketed by pharmaceutical sponsors. We emphasize further study of this relation and suggest three principles - full disclosure, policies against {"}outcome bias,{"} and educational opportunities - that may help manage industry-academia conflicts of interest that could otherwise jeopardize the credibility of pharmaceutical research presented at scientific meetings.",
author = "Thomas Finucane and Boult, {Chad E.}",
year = "2004",
month = "12",
day = "1",
doi = "10.1016/j.amjmed.2004.05.029",
language = "English (US)",
volume = "117",
pages = "842--845",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Association of funding and findings of pharmaceutical research at a meeting of a medical professional society

AU - Finucane, Thomas

AU - Boult, Chad E.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - To evaluate the association between funding and findings of pharmaceutical research presented at an annual meeting of a medical professional society. We reviewed the abstracts of all papers and posters presented at the annual meeting of a medical professional society. Two independent raters classified each study of a drug (n = 48) as either positive (favoring the drug studied) or negative, and as either funded by a pharmaceutical company or not. We computed κ and chi-squared statistics to evaluate the agreement between the raters, as well as the association between the results and the sponsorship of the study. Thirty studies of drugs (63%) were supported by pharmaceutical companies, all of which reported positive results. Of the 18 studies (37%) not supported by pharmaceutical companies, 67% reported positive results. The association between pharmaceutical funding and positive findings was statistically significant (P = 0.0007). At this scientific meeting, research funding from pharmaceutical companies was associated with study findings that supported the use of drugs marketed by pharmaceutical sponsors. We emphasize further study of this relation and suggest three principles - full disclosure, policies against "outcome bias," and educational opportunities - that may help manage industry-academia conflicts of interest that could otherwise jeopardize the credibility of pharmaceutical research presented at scientific meetings.

AB - To evaluate the association between funding and findings of pharmaceutical research presented at an annual meeting of a medical professional society. We reviewed the abstracts of all papers and posters presented at the annual meeting of a medical professional society. Two independent raters classified each study of a drug (n = 48) as either positive (favoring the drug studied) or negative, and as either funded by a pharmaceutical company or not. We computed κ and chi-squared statistics to evaluate the agreement between the raters, as well as the association between the results and the sponsorship of the study. Thirty studies of drugs (63%) were supported by pharmaceutical companies, all of which reported positive results. Of the 18 studies (37%) not supported by pharmaceutical companies, 67% reported positive results. The association between pharmaceutical funding and positive findings was statistically significant (P = 0.0007). At this scientific meeting, research funding from pharmaceutical companies was associated with study findings that supported the use of drugs marketed by pharmaceutical sponsors. We emphasize further study of this relation and suggest three principles - full disclosure, policies against "outcome bias," and educational opportunities - that may help manage industry-academia conflicts of interest that could otherwise jeopardize the credibility of pharmaceutical research presented at scientific meetings.

UR - http://www.scopus.com/inward/record.url?scp=10044254514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10044254514&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2004.05.029

DO - 10.1016/j.amjmed.2004.05.029

M3 - Article

C2 - 15589488

AN - SCOPUS:10044254514

VL - 117

SP - 842

EP - 845

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 11

ER -